{
    "NCT05979779": {
        "model_response": [
            "Development and verification of a microchip fabricated using a poly-di-methyl-siloxane-gel as substrate.\nIn this study, a novel microchip fabricated using poly-di-methyl-siloxane-gel (PDMS) as substrate is introduced. This method has been used to fabricate a microchip for high-performance liquid chromatography, but due to the fragility of PDMS-gel caused by the use of a very thin membrane for separation and the inappropriate sealing process, these microchips may not have been applied to other techniques in a routine manner. By incorporating the following improvements, the method has proven to be quite stable under harsher environments than other microchip-based techniques. First, a thicker PDMS membrane was used in the microfabrication process, which improves the robustness of the fabricated microchip. Also, the fabrication process was modified so that the sealing process did not affect the stability of the membrane. As a result, by incorporating these improvements, these newly developed microchips could be used to conduct chromatographic operation under almost any condition, including a drastic change in temperature, a severe change of operating pressure, and the introduction of strong polar and non-polar solvents. Prolonged neomycin exposure induces apoptosis in primary auditory neurons: a primary culture study\nExposure to ototoxic drugs increases the incidence and prevalence of deafness in human and animals. Many ototoxic drugs are aminoglycosides that have the potential to cause permanent hearing loss not due to direct structural damage. The present study was designed to examine the molecular mechanisms underlying the aminoglycoside toxicity, focusing on the induction of apoptosis in primary auditory neurons. We established explant culture of the rat cochlea, and examined the exposure of primary auditory neuron cultures to low concentration (0.2\u20134\u2009mM) of aminoglycoside antibiotic neomycin. In the morphological analysis of neomycin exposure in primary auditory neurons, the neuronal cells started to round up after 8\u2009h, and became apoptotic after 12 (early",
            "Yes, the placebo arm will include obese subjects with Type 2 Diabetes at risk of Nonalcoholic Steatohepatitis. They will receive planned doses of placebo and will not receive any treatment benefit from the study drug. The primary purpose of this arm will also be to evaluate the safety and efficacy of HU6 in improving liver fat content. The placebo and Active Treatment: HU6 arms will have similar timelines, visits, assessments, monitoring activities, and the same study drug. Except for the Active Treatment: HU6 arm, only the placebo arm will provide a study drug and therefore will have to be provided with additional supplies of placebo. The duration of the treatment and follow-up periods should be as short as possible, to allow quicker access to potentially beneficial outcomes. We require detailed information about these trial design elements. Your data will not be shared by the investigators to other investigators; it is confidential to all relevant aspects of your trial. Effects of Tetrahymena pyriformis lysate on the course of herpes infection\nThe use of Tetrahymena pyriformis lysate during the course of herpes infection of chick embryos was shown to afford almost consistent protection of the embryos against the death rate which might ordinarily have occurred owing to the infection. A new method of measuring the concentration of glutathione in human blood\n1 The spectrophotometric analysis for the determination of the concentration of glutathione in erythrocytes that uses 5,5\u2032\u2010dithiobis\u2010(2\u2010nitrobenzoic acid) as a reagent has been successfully applied to serum (Porter & Pace, 1966) and plasma (Porter, 1966). The method does not involve the use of trichloroacetic acid or sulphosalicylic acid, both of which tend to deplete the sample of glutathione. 2 It has now been shown that a high concentration of plasma inhibited the development of absorbance at 412 nm. Thus the concentration of glutathione in serum is probably lower than its concentration in plasma. 3 The concentration of glutathione is not significantly changed by the",
            "Yes, that's correct. Correlation Between Serum 25-hydroxyvitamin D3 Level and Serum C reactive Protein Levels in Patients with Type 2 Diabetes\n\nBackground and Aims: Vitamin D has been linked with a wide range of diseases and has a well-defined link with inflammation. C-reactive protein (CRP) is an inflammatory marker that is used to determine the level of systemic inflammation resulting from different diseases. Vitamin D is known to affect the levels of CRP, and also CRP is known to affect the levels of vitamin D. To have a better understanding of the relationship between vitamin D and inflammation, we correlated the serum CRP levels with serum vitamin D status in patients with type 2 diabetes mellitus (T2DM) who presented to the outpatient clinics in National Health Center. Patients and Methods: We evaluated the serum level of vitamin D (25-hydroxyvitamin D or 25-OHD) by using commercial radioimmunoassay kits in 106 patients with T2DM compared with 43 subjects without diabetes. Their serum C-reactive protein (CRP) was measured using Beckman Coulter machine, and correlation analysis between 25-OHD and CRP levels was done using SPSS version 21.0. Results and Conclusion: We observed a significant inverse relationship between the serum level of 25-OHD and CRP levels, and also a trend correlation of 25-OHD values below 75 nmol/L with elevated CRP levels.\n\n# Introduction\nA c c o r d i n g t o t h e t h i r d U n i t e d Na-tions (UN) Diabetes Atlas, around 1 in 2 persons with diabetes across the world does not know that they have diabetes.   Global estimates of diabetes prevalence for 2013 and projections for 2035, Guariguata   The recent meta-analysis of 30 cohort studies found that diabetes is significantly associated with a 54% increased risk for cardiovasc"
        ],
        "eval_results": [
            "Match prediction: 0\n\nExplanation:\nThe model output does not mention any study arms related to the treatment of obese subjects with Type 2 Diabetes at risk of Nonalcoholic Steatohepatitis (NASH). The model output is discussing the development and verification of a microchip fabricated using a poly-di-methyl-siloxane-gel as substrate, and the effects of neomycin exposure on primary auditory neurons. These topics are completely unrelated to the groundtruth study arms, which are focused on evaluating the efficacy of the drug HU6 compared to a placebo in the target patient population. Therefore, the study arms mentioned in the model output are not present in the groundtruth study arm table, and the match prediction is 0.",
            "Match prediction: 1\n\nExplanation:\nThe model output mentions the \"placebo comparator arm\" and the \"Active Treatment: HU6\" arm, which are both present in the groundtruth study arm table. The model output provides details about the placebo comparator arm, stating that it will include obese subjects with Type 2 Diabetes at risk of Nonalcoholic Steatohepatitis and that they will receive a placebo. This matches the information provided in the groundtruth study arm table, which lists the \"Placebo Comparator: Placebo Comparator Non-active study drug\" arm.\n\nAdditionally, the model output mentions the \"Active Treatment: HU6\" arm, which also matches the information in the groundtruth study arm table, which lists the \"Experimental: Active Treatment: HU6 Planned doses of HU6\" arm.\n\nTherefore, the study arms mentioned in the model's output are fully included in the groundtruth study arm table, and the match prediction is 1.",
            "Match prediction: 0\n\nExplanation:\nThe model output does not mention any study arms or interventions. It describes a study that investigated the correlation between serum 25-hydroxyvitamin D3 levels and serum C-reactive protein levels in patients with type 2 diabetes. This information is not present in the provided groundtruth study arm table, which describes a different study with experimental and placebo comparator arms involving the drug HU6. Therefore, the study arms mentioned in the model output are not present in the groundtruth study arm table, and the match prediction is 0."
        ]
    }
}